TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:TAK - US8740602052 - ADR
16.16 USD
-0.17 (-1.04%)
16.16 USD
0 (0%)
Overall TAK gets a fundamental rating of 5 out of 10. We evaluated TAK against 191 industry peers in the Pharmaceuticals industry. TAK has an excellent profitability rating, but there are concerns on its financial health. TAK has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- In the past year TAK was profitable.
- TAK had a positive operating cash flow in the past year.
- Each year in the past 5 years TAK has been profitable.
- Each year in the past 5 years TAK had a positive operating cash flow.
1.2 Ratios
- TAK has a Return On Assets of 0.23%. This is in the better half of the industry: TAK outperforms 78.01% of its industry peers.
- TAK has a better Return On Equity (0.46%) than 79.58% of its industry peers.
- TAK has a Return On Invested Capital of 1.87%. This is in the better half of the industry: TAK outperforms 79.06% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for TAK is significantly below the industry average of 12.84%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.23% | ||
| ROE | 0.46% | ||
| ROIC | 1.87% |
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.62%
ROIC(5y)2.55%
1.3 Margins
- With a decent Profit Margin value of 0.75%, TAK is doing good in the industry, outperforming 78.01% of the companies in the same industry.
- In the last couple of years the Profit Margin of TAK has grown nicely.
- With an excellent Operating Margin value of 8.46%, TAK belongs to the best of the industry, outperforming 80.10% of the companies in the same industry.
- TAK's Operating Margin has improved in the last couple of years.
- Looking at the Gross Margin, with a value of 64.60%, TAK is in the better half of the industry, outperforming 74.35% of the companies in the same industry.
- TAK's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.46% | ||
| PM (TTM) | 0.75% | ||
| GM | 64.6% |
OM growth 3Y-8.47%
OM growth 5Y6.13%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), TAK is creating some value.
- Compared to 1 year ago, TAK has more shares outstanding
- The number of shares outstanding for TAK has been increased compared to 5 years ago.
- Compared to 1 year ago, TAK has an improved debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of 1.23, we must say that TAK is in the distress zone and has some risk of bankruptcy.
- TAK has a Altman-Z score (1.23) which is comparable to the rest of the industry.
- TAK has a debt to FCF ratio of 5.04. This is a neutral value as TAK would need 5.04 years to pay back of all of its debts.
- Looking at the Debt to FCF ratio, with a value of 5.04, TAK belongs to the top of the industry, outperforming 83.25% of the companies in the same industry.
- TAK has a Debt/Equity ratio of 0.61. This is a neutral value indicating TAK is somewhat dependend on debt financing.
- TAK has a worse Debt to Equity ratio (0.61) than 68.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 5.04 | ||
| Altman-Z | 1.23 |
ROIC/WACC1.16
WACC1.62%
2.3 Liquidity
- TAK has a Current Ratio of 1.36. This is a normal value and indicates that TAK is financially healthy and should not expect problems in meeting its short term obligations.
- TAK has a Current ratio of 1.36. This is in the lower half of the industry: TAK underperforms 73.82% of its industry peers.
- TAK has a Quick Ratio of 1.36. This is a bad value and indicates that TAK is not financially healthy enough and could expect problems in meeting its short term obligations.
- TAK's Quick ratio of 0.76 is on the low side compared to the rest of the industry. TAK is outperformed by 84.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.76 |
3. Growth
3.1 Past
- TAK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -88.38%.
- The Earnings Per Share has been growing by 19.20% on average over the past years. This is quite good.
- TAK shows a decrease in Revenue. In the last year, the revenue decreased by -2.84%.
- Measured over the past years, TAK shows a small growth in Revenue. The Revenue has been growing by 6.84% on average per year.
EPS 1Y (TTM)-88.38%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%-112.87%
Revenue 1Y (TTM)-2.84%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%-5.38%
3.2 Future
- The Earnings Per Share is expected to grow by 43.97% on average over the next years. This is a very strong growth
- The Revenue is expected to decrease by -0.03% on average over the next years.
EPS Next Y83.65%
EPS Next 2Y68.19%
EPS Next 3Y43.97%
EPS Next 5YN/A
Revenue Next Year-1.77%
Revenue Next 2Y-0.66%
Revenue Next 3Y-0.03%
Revenue Next 5YN/A
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 230.86, the valuation of TAK can be described as expensive.
- Based on the Price/Earnings ratio, TAK is valued a bit cheaper than the industry average as 75.39% of the companies are valued more expensively.
- When comparing the Price/Earnings ratio of TAK to the average of the S&P500 Index (27.38), we can say TAK is valued expensively.
- TAK is valuated quite expensively with a Price/Forward Earnings ratio of 26.43.
- TAK's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. TAK is cheaper than 73.82% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 24.29. TAK is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 230.86 | ||
| Fwd PE | 26.43 |
4.2 Price Multiples
- TAK's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. TAK is cheaper than 87.43% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, TAK is valued cheaply inside the industry as 92.67% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.74 | ||
| EV/EBITDA | 10.66 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- TAK has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as TAK's earnings are expected to grow with 43.97% in the coming years.
PEG (NY)2.76
PEG (5Y)12.03
EPS Next 2Y68.19%
EPS Next 3Y43.97%
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 3.86%, TAK has a reasonable but not impressive dividend return.
- Compared to an average industry Dividend Yield of 0.40, TAK pays a better dividend. On top of this TAK pays more dividend than 96.86% of the companies listed in the same industry.
- TAK's Dividend Yield is rather good when compared to the S&P500 average which is at 1.84.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.86% |
5.2 History
- The dividend of TAK has a limited annual growth rate of 1.18%.
- TAK has paid a dividend for at least 10 years, which is a reliable track record.
- TAK has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)1.18%
Div Incr Years2
Div Non Decr Years3
5.3 Sustainability
- TAK pays out 935.06% of its income as dividend. This is not a sustainable payout ratio.
- TAK's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP935.06%
EPS Next 2Y68.19%
EPS Next 3Y43.97%
16.16
-0.17 (-1.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-30 2025-10-30/dmh
Earnings (Next)01-28 2026-01-28
Inst Owners47.21%
Inst Owner Change-0.03%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap51.05B
Revenue(TTM)4.42T
Net Income(TTM)33.08B
Analysts74.44
Price Target16.52 (2.23%)
Short Float %0.37%
Short Ratio4.12
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.86% |
Yearly Dividend0.61
Dividend Growth(5Y)1.18%
DP935.06%
Div Incr Years2
Div Non Decr Years3
Ex-Date03-30 2026-03-30 (100)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-41.49%
Min EPS beat(2)-121.92%
Max EPS beat(2)38.94%
EPS beat(4)1
Avg EPS beat(4)-35.42%
Min EPS beat(4)-121.92%
Max EPS beat(4)38.94%
EPS beat(8)4
Avg EPS beat(8)-31.47%
EPS beat(12)6
Avg EPS beat(12)-33.69%
EPS beat(16)7
Avg EPS beat(16)-40.61%
Revenue beat(2)0
Avg Revenue beat(2)-6.4%
Min Revenue beat(2)-6.76%
Max Revenue beat(2)-6.04%
Revenue beat(4)0
Avg Revenue beat(4)-3.84%
Min Revenue beat(4)-6.76%
Max Revenue beat(4)-0.48%
Revenue beat(8)4
Avg Revenue beat(8)3.03%
Revenue beat(12)7
Avg Revenue beat(12)3.44%
Revenue beat(16)11
Avg Revenue beat(16)3.69%
PT rev (1m)1.64%
PT rev (3m)-6.4%
EPS NQ rev (1m)1.04%
EPS NQ rev (3m)21.49%
EPS NY rev (1m)-6.66%
EPS NY rev (3m)-18.71%
Revenue NQ rev (1m)0.04%
Revenue NQ rev (3m)1.51%
Revenue NY rev (1m)-0.24%
Revenue NY rev (3m)-0.68%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 230.86 | ||
| Fwd PE | 26.43 | ||
| P/S | 1.83 | ||
| P/FCF | 8.74 | ||
| P/OCF | 6.72 | ||
| P/B | 1.13 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.66 |
EPS(TTM)0.07
EY0.43%
EPS(NY)0.61
Fwd EY3.78%
FCF(TTM)1.85
FCFY11.44%
OCF(TTM)2.4
OCFY14.88%
SpS8.85
BVpS14.29
TBVpS-3.21
PEG (NY)2.76
PEG (5Y)12.03
Graham Number4.74
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.23% | ||
| ROE | 0.46% | ||
| ROCE | 3.03% | ||
| ROIC | 1.87% | ||
| ROICexc | 1.99% | ||
| ROICexgc | 8.07% | ||
| OM | 8.46% | ||
| PM (TTM) | 0.75% | ||
| GM | 64.6% | ||
| FCFM | 20.88% |
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.62%
ROIC(5y)2.55%
ROICexc(3y)2.76%
ROICexc(5y)2.73%
ROICexgc(3y)14.61%
ROICexgc(5y)14.15%
ROCE(3y)4.25%
ROCE(5y)4.14%
ROICexgc growth 3Y-6.2%
ROICexgc growth 5Y8.09%
ROICexc growth 3Y-3.88%
ROICexc growth 5Y10.72%
OM growth 3Y-8.47%
OM growth 5Y6.13%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
F-Score6
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 5.04 | ||
| Debt/EBITDA | 3.9 | ||
| Cap/Depr | 37.3% | ||
| Cap/Sales | 6.28% | ||
| Interest Coverage | 3.04 | ||
| Cash Conversion | 107.4% | ||
| Profit Quality | 2788.5% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.76 | ||
| Altman-Z | 1.23 |
F-Score6
WACC1.62%
ROIC/WACC1.16
Cap/Depr(3y)69.03%
Cap/Depr(5y)56.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)9.44%
Profit Quality(3y)309.71%
Profit Quality(5y)308.48%
High Growth Momentum
Growth
EPS 1Y (TTM)-88.38%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%-112.87%
EPS Next Y83.65%
EPS Next 2Y68.19%
EPS Next 3Y43.97%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.84%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%-5.38%
Revenue Next Year-1.77%
Revenue Next 2Y-0.66%
Revenue Next 3Y-0.03%
Revenue Next 5YN/A
EBIT growth 1Y-31.07%
EBIT growth 3Y-0.52%
EBIT growth 5Y13.39%
EBIT Next Year435.35%
EBIT Next 3Y77.31%
EBIT Next 5YN/A
FCF growth 1Y613.62%
FCF growth 3Y-8.86%
FCF growth 5Y9.4%
OCF growth 1Y24.54%
OCF growth 3Y-2%
OCF growth 5Y9.54%
TAKEDA PHARMACEUTIC-SP ADR / TAK FAQ
What is the fundamental rating for TAK stock?
ChartMill assigns a fundamental rating of 5 / 10 to TAK.
What is the valuation status for TAK stock?
ChartMill assigns a valuation rating of 5 / 10 to TAKEDA PHARMACEUTIC-SP ADR (TAK). This can be considered as Fairly Valued.
What is the profitability of TAK stock?
TAKEDA PHARMACEUTIC-SP ADR (TAK) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for TAK stock?
The Price/Earnings (PE) ratio for TAKEDA PHARMACEUTIC-SP ADR (TAK) is 230.86 and the Price/Book (PB) ratio is 1.13.
How financially healthy is TAKEDA PHARMACEUTIC-SP ADR?
The financial health rating of TAKEDA PHARMACEUTIC-SP ADR (TAK) is 3 / 10.